Cefotaxime Pediatric Dose — Antimicrobial Reference
Cefotaxime is a third-generation cephalosporin that exerts bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins. It demonstrates broad-spectrum coverage against gram-negative organisms and is active against many gram-positive pathogens, making it a cornerstone agent in the empiric treatment of serious pediatric infections. Primary indications include sepsis, pneumonia, urinary tract infections, and bacterial meningitis in neonates, infants, and children.
Pediatric Dosing
| Indication | Dose | Frequency | Route |
|---|---|---|---|
| General infections | 50 mg/kg/dose | Every 8 hours | IV |
| Meningitis | 50 mg/kg/dose | Every 6 hours | IV |
The adult dose is 2 g IV every 8 hours; consult institutional protocol for weight-based upper dose limits in heavier pediatric patients.
Worked example (general infection): For a 20 kg child: 20 × 50 mg/kg = 1,000 mg (1 g) IV every 8 hours. Worked example (meningitis): For the same 20 kg child: 20 × 50 mg/kg = 1,000 mg (1 g) IV every 6 hours.
Indications and Clinical Context
Cefotaxime is indicated for moderate-to-severe bacterial infections in pediatric patients, including community-acquired pneumonia, pyelonephritis, intra-abdominal infections, sepsis, and neonatal sepsis. The increased dosing frequency for meningitis (every 6 hours vs. every 8 hours) reflects the need for sustained CNS drug exposure, as third-generation cephalosporins rely on adequate cerebrospinal fluid penetration to achieve bactericidal concentrations against common causative pathogens such as Streptococcus pneumoniae, Neisseria meningitidis, and gram-negative bacilli.
Cefotaxime is frequently referenced in PALS and Pediatric Infectious Diseases Society guidelines as an appropriate empiric agent for serious bacterial infections where gram-negative coverage is required. It is particularly valued in neonates and young infants given its established safety profile and favorable pharmacokinetics in this age group.
Administration and Monitoring
Cefotaxime is administered intravenously; it may be given as an IV bolus over 3–5 minutes or as a short infusion over 15–30 minutes. Ensure adequate IV or IO access prior to administration in emergency settings. Dose adjustments may be required in renal impairment — consult institutional protocol for guidance on frequency modification.
- Monitoring: Observe for hypersensitivity reactions, particularly in patients with known beta-lactam or penicillin allergy (cross-reactivity is low but possible).
- Common adverse effects: Rash, diarrhea, transient elevation of hepatic transaminases, and eosinophilia.
- Contraindications: Known hypersensitivity to cefotaxime or other cephalosporins; use with caution in patients with documented severe penicillin allergy.
- Max dose: Not explicitly defined in source; consult institutional protocol for patients approaching adult weight thresholds (adult dose reference: 2 g IV every 8 hours).
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.